Table 1. Patient characteristics.
| Total number of patients | 93 |
|---|---|
| Male : Female | 58 : 35 |
| Age, y | 69.6 ± 12.8 |
| BMI, kg/m2 | 24.1 ± 4.8 |
| Risk factors (number of patients) | |
| Hypertension | 76 |
| Diabetes | 30 |
| Dyslipidemia | 41 |
| Smoking | 11 |
| Hemodialysis | 11 |
| NYHA | 2.1 ± 1.1 |
| Coronary artery disease (number of patients) | 42 |
| 0-vessel disease | 51 |
| 1-vessel disease | 9 |
| 2-vessel disease | 4 |
| 3-vessel disease | 29 |
| Cardiovascular surgery (number of patients) | |
| CABG | 28 |
| AVR or TAVI | 22 |
| Other valve replacement / repair | 11 |
| Combined | 14 |
| Aortic disease (TAR, TEVAR, et al) | 12 |
| Others | 6 |
| Drugs ((number of patients) | |
| β-blockers | 45 |
| Ca-blockers | 31 |
| ACE-I/ARB | 48 |
| Diuretics | 42 |
| Statin | 43 |
| Sulfonylurea | 9 |
| α-GI | 6 |
| Biguanide | 3 |
| DPP4 inhibitor | 21 |
| Insulin | 8 |
| SGLT2 | 1 |
| Thiazolidinedione | 1 |
The mean ± SD values are shown.
NYHA, New York Heart Association; CABG, coronary artery bypass grafting; AVR, aortic valve replacement; TAVI, transcatheter aortic valve implantation; TAR, total arch replacement; TEVAR, thoracic endovascular aortic repair; ACE1, angiotensin converting enzyme inhibitor; angiotensin II receptor blocker, ARB; α-glucosidase inhibitor, α-GI: dipeptidyl peptidase-4 inhibitor, DPP-4 inhibitor; sodium glucose cotransporter 2 inhibitor, SGLT2 inhibitor